Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

NCT07090369 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Olaparib (300 mg BID)
DRUG: Pembrolizumab
RADIATION: 177Lu-PSMA-I&T

Sponsor

Peter MacCallum Cancer Centre, Australia